RT Journal Article
SR Electronic
T1 Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.23.24305825
DO 10.1101/2024.04.23.24305825
A1 Bartos, Laura M
A1 Quach, Stefanie
A1 Zenatti, Valerio
A1 Kirchleitner, Sabrina V
A1 Blobner, Jens
A1 Wind-Mark, Karin
A1 Kolabas, Zeynep Ilgin
A1 Ulukaya, Selin
A1 Holzgreve, Adrien
A1 Ruf, Viktoria C
A1 Kunze, Lea H
A1 Kunte, Sebastian T
A1 Hoermann, Leonie
A1 Härtel, Marlies
A1 Park, Ha Eun
A1 Groß, Mattes
A1 Franzmeier, Nicolai
A1 Zatcepin, Artem
A1 Zounek, Adrian
A1 Kaiser, Lena
A1 Riemenschneider, Markus J
A1 Perneczky, Robert
A1 Rauchmann, Boris-Stephan
A1 Stöcklein, Sophia
A1 Ziegler, Sibylle
A1 Herms, Jochen
A1 Ertürk, Ali
A1 Tonn, Joerg C
A1 Thon, Niklas
A1 von Baumgarten, Louisa
A1 Prestel, Matthias
A1 Tahirovic, Sabina
A1 Albert, Nathalie L
A1 Brendel, Matthias
YR 2024
UL http://medrxiv.org/content/early/2024/04/24/2024.04.23.24305825.abstract
AB Local therapy strategies still provide only limited success in the treatment of glioblastoma, the most frequent primary brain tumor in adults, indicating global involvement of the brain in this fatal disease. To study the impact of neuroinflammation distant of the primary tumor site on the clinical course of patients with glioblastoma, we performed translocator protein (TSPO)-PET in patients with newly diagnosed glioblastoma, glioma WHO 2 and healthy controls and compared signals of the non-lesion (i.e. contralateral) hemisphere. Back-translation in syngeneic glioblastoma mice was used to characterize PET alterations on a cellular level. Ultimately, multiplex gene expression analyses served to profile immune cells in remote brain. Our study revealed elevated TSPO-PET signals in contralateral hemispheres of patients with newly diagnosed glioblastoma compared to healthy controls. Contralateral TSPO was associated with persisting epilepsy and short survival independent of the tumor phenotype. Back-translation pinpointed myeloid cells as the source of TSPO-PET signal increases and revealed a complex immune signature comprised of joint myeloid cell activation and immunosuppression in distant brain regions. In brief, neuroinflammation within the contralateral hemisphere is associated with poor outcome in patients with newly diagnosed glioblastoma. TSPO-PET serves to detect patients with global neuroinflammation who may benefit from immunomodulatory strategies.Competing Interest StatementNLA and MB are members of the Neuroimaging Committee of the EANM. JCT received research grants from Novocure and Munich Surgical Imaging and a speaker honorarium from Seagen. NLA received funding from Novocure. MB received speaker honoraria from Roche, GE healthcare and Life Molecular Imaging and is an advisor of Life Molecular Imaging. VCR received speaker honoraria from Novocure. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Funding StatementThis project was partly funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (FOR 2858 project numbers 421887978 and 422188432 and Research Training Group GRK 2274). NLA is supported by a research grant of the Else Kroener-Fresenius-Stiftung. MB was funded by the Deutsche Forschungsgemeinschaft (DFG) under Germanys Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy, ID 390857198). SVK was supported by the Verein zur Foerderung von Wissenschaft und Forschung an der Medizinischen Fakultaet der LMU Muenchen (WiFoMed) and the Friedrich-Baur-Stiftung. AH received funding by the Bavarian Cancer Research Center (BZKF) and is currently funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, 545058105.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Ludwig-Maximilians-University gave ethical approval for this work (approval number 17-457, approval numbers for data on healthy individuals 601-16, 17-569, 17-755)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data needed to evaluate the conclusions of Fig. 1-5 are present in the paper and/or the Supplementary Materials. Imaging data will be shared in DICOM format upon reasonable request to the corresponding author.